N30 Pharmaceuticals commences dosing in N6022 GSNOR trial for asthma, COPD and IBD

Published on September 8, 2010 at 7:13 AM · No Comments

N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

SOURCE N30 Pharmaceuticals, LLC

9959c57d-8f7a-4d12-88e6-79d1f65802c3|0|.0

Posted in: Drug Trial News | Medical Condition News | Disease/Infection News

Tags: Antibody, Anti-Inflammatory, Asthma, Biomarker, Cardiovascular Disease, Inflammatory Bowel Disease, Monoclonal Antibody, Pharmacokinetics, Respiratory Disease

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory painZalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients s...
Human gliomas release excess levels of glutamate and trigger seizuresGlioma, one of the most deadly and common types of brain tumor, is often associated with seizures, b...
Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemiaAlnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation...
Painful periods at early age doubles risk of endometriosisQueensland Institute of Medical Research scientists have identified a new link between strong period...
Signaling molecules may link certain actions of B cells to solid tumor growth: StudyCancer researchers studying the immune system have identified a previously unrecognized set of targe...
New stem cell therapies to feature at 5th Annual Stem Cell Summit in NYCSix new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th A...
User-friendly overview of pathology, a resource for all medical studentsResearch and Markets (http://www.researchandmarkets.com/research/fccd5e/pathology_at_a_gla) has anno...
Aspirin shown to be beneficial before heart surgerySurgeons who have been advising their patients to avoid taking aspirin in the days before surgery be...
Analysis shows Remicade reduces pain associated with Crohn's diseaseAccording to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infli...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.